A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected PDAC
NCT05968326
Site status not listed — check the official record
- Conditions
- Adenocarcinoma, Pancreatic Ductal
- Interventions
- Autogene cevumeran, Atezolizumab, mFOLFIRINOX
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 30
- States / cities
- Los Angeles, California • Newport Beach, California • San Francisco, California + 22 more